AI Becomes Essential in Drug Discovery
In 2026, AI has become not just an option but an essential element in the pharmaceutical and biotech industry. Over 90% of global pharmaceutical companies have integrated AI into their drug development pipelines, and AI-derived drug candidates entering clinical trials are surging.
The Korean government actively supports AI drug development. The MFDS has established new clinical outcome evaluation models incorporating AI and digital healthcare technology and expanded fast-track listing procedures for all innovative drugs.
How AI Transforms Drug Development
Traditional vs. AI-Based Process
| Stage | Traditional | AI-Based | Time Savings |
|-------|-----------|----------|-------------|
| Target Discovery | 3-5 years | 6-12 months | 70% reduction |
| Lead Optimization | 2-3 years | 3-6 months | 80% reduction |
| Preclinical | 1-2 years | 6-12 months | 40% reduction |
| Clinical Design | 6-12 months | 1-3 months | 70% reduction |
| Total Cost | 2-3T KRW | 500B-1T KRW | 50-70% savings |
Core AI Application Areas
1. Target Identification
Disease-related target discovery through genomic and proteomic big data analysisDrug Repositioning: Finding new indications for existing drugsMulti-omics data integration analysis2. Molecular Design
Generative AI for automatic optimal molecular structure designADMET prediction (absorption, distribution, metabolism, excretion, toxicity)Deriving practical candidates considering synthetic feasibility3. Clinical Trial Optimization
Accelerated patient recruitment: Auto-identification through EMR analysisDose optimization: Simulation-based optimal dosingBiomarker discovery: Response-predictive biomarkers for improved success ratesReal-world data (RWD) utilization to reduce clinical trial scale4. Safety Prediction
Clinical adverse event prediction based on preclinical toxicity dataCross-analysis with similar drug databasesLong-term safety profile simulationAI Utilization Strategies for Biotech SMEs
Strategy 1: Partner with AI Platform Companies
Building in-house AI capabilities is time and cost intensive. Partnering with specialized AI bio platforms is more efficient.
Domestic: Standigm, Pharos iBio, Deargen, etc.Global: Insilico Medicine, Recursion, Exscientia, etc.Collaboration model: Milestone-based royalty contracts to minimize upfront costsStrategy 2: Leverage Public AI Infrastructure
National Bio Big Data: Free/affordable access to genomic and clinical dataAI Hub: Public AI models and datasets for drug developmentKISTI Supercomputing: Molecular simulation computing resourcesStrategy 3: AI+CRO Combined Model
Leverage CRO AI capabilitiesApply AI-based Adaptive Clinical Design30~50% shorter clinical periods, 20~40% cost reductionGovernment Support Programs Overview
R&D Support
| Program | Content | Scale |
|---------|---------|-------|
| Multi-ministry Drug Development | Full preclinical-to-clinical support | Up to billions KRW per project |
| AI Drug Discovery Platform | AI model and data construction | 1-3B KRW annually |
| Phase 3 Specialized Fund | Investment linkage | Total 150B KRW |
| TIPS Bio | Early-stage R&D | Up to 800M KRW |
Regulatory Support
Innovative medical device designation: AI-based diagnostic/therapeutic softwareFast-track review: Priority review for AI-leveraged innovative drugsRegulatory sandbox: Regulatory flexibility through demonstration special approvalTax Benefits
R&D tax credit: Up to 40% deduction for AI-related R&D costs (SMEs)National strategic technology credit: Additional benefits as AI is designated strategic technologyKey Checklist for AI Drug Discovery Success
Data quality: AI performance is proportional to data qualityIP strategy: Patent filing strategy for AI-generated moleculesRegulatory readiness: Confirm regulatory acceptance of AI-based evidenceTalent: Recruit bio+AI convergence talent or engage external expertsPartnership network: Build collaboration systems with AI companies, CROs, and academiaKITIM Bio & AI Consulting
KITIM provides comprehensive consulting for biotech SMEs leveraging AI in drug development.
AI adoption assessment: Recommend AI utilization strategies suited to company pipelinesGovernment R&D matching: Discover and support applications for AI drug development programsPartnership advisory: Design collaboration structures with AI biotechs and CROs